FcγRIIB inhibits the development of atherosclerosis in low-density lipoprotein receptor-deficient mice

Journal of Immunology

Volumn 184, Issue 5, 2010, Pages 2253-2260

  Zhao, Ming ^a,c   Wigren, Maria ^a   Dunér, Pontus ^a   Kolbus, Daniel ^a   Olofsson, Katarina E ^a   Björkbacka, Harry ^a   Nilsson, Jan ^a   Fredrikson, Gunilla Nordin ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b MALMÖ UNIVERSITY   (Sweden)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CHOLESTEROL; CONCANAMYCIN A; FC RECEPTOR IIB; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; FC RECEPTOR; FCGR2B PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; B LYMPHOCYTE; BONE MARROW CELL; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CONTROL GROUP; CONTROLLED STUDY; CYTOKINE PRODUCTION; DESCENDING AORTA; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; LIPID DIET; LIPOPROTEIN BLOOD LEVEL; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; STAINING; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CELL CULTURE; CYTOLOGY; FAT INTAKE; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; SPLEEN;

ANIMALS; ATHEROSCLEROSIS; B-LYMPHOCYTES; BONE MARROW TRANSPLANTATION; CELL PROLIFERATION; CELLS, CULTURED; CHOLESTEROL; DIETARY FATS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, IGG; RECEPTORS, LDL; SPLEEN; T-LYMPHOCYTES; TH1 CELLS; TH2 CELLS; TRIGLYCERIDES;

EID: 77951906484     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902654     Document Type: Article

References (51)

1. Ross, R. 1999. Atherosclerosis is an inflammatory disease. Am. Heart J. 138: S419-S420.
2. Hansson, G. K. 2005. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352: 1685-1695.
3. Palinski, W., and J. L. Witztum. 2000. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J. Intern. Med. 247: 371-380.
4. Nilsson, J., G. K. Hansson, and P. K. Shah. 2005. Immunomodulation of atherosclerosis: implications for vaccine development. Arterioscler. Thromb. Vasc. Biol. 25: 18-28.
5. Hansson, G. K., and P. Libby. 2006. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 6: 508-519.
6. Binder, C. J., M. K. Chang, P. X. Shaw, Y. I. Miller, K. Hartvigsen, A. Dewan, and J. L. Witztum. 2002. Innate and acquired immunity in atherogenesis. Nat. Med. 8: 1218-1226.
7. Hansson, G. K., P. Libby, U. Schönbeck, and Z. Q. Yan. 2002. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res. 91: 281-291.
8. Palinski, W., E. Miller, and J. L. Witztum. 1995. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc. Natl. Acad. Sci. USA 92: 821-825.
9. Ameli, S., A. Hultgårdh-Nilsson, J. Regnström, F. Calara, J. Yano, B. Cercek, P. K. Shah, and J. Nilsson. 1996. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler. Thromb. Vasc. Biol. 16: 1074-1079.
10. Nicoletti, A., S. Kaveri, G. Caligiuri, J. Bariéty, and G. K. Hansson. 1998. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J. Clin. Invest. 102: 910-918.
11. Caligiuri, G., A. Nicoletti, B. Poirier, and G. K. Hansson. 2002. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J. Clin. Invest. 109: 745-753.
12. Fredrikson, G. N., B. Hedblad, G. Berglund, R. Alm, M. Ares, B. Cercek, K.-Y. Chyu, P. K. Shah, and J. Nilsson. 2003. Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 23: 872-878.
13. Fredrikson, G. N., I. Söderberg, M. Lindholm, P. Dimayuga, K.-Y. Chyu, P. K. Shah, and J. Nilsson. 2003. Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences. Arterioscler. Thromb. Vasc. Biol. 23: 879-884.
14. Fredrikson, G. N., L. Andersson, I. Söderberg, P. Dimayuga, K.-Y. Chyu, P. K. Shah, and J.Nilsson. 2005.Atheroprotective immunization with MDA-modified apoB-100 peptide sequences is associated with activation of Th2 specific antibody expression. Autoimmunity 38: 171-179.
15. Fredrikson, G. N., H. Björkbacka, I. Söderberg, I. Ljungcrantz, and J. Nilsson. 2008. Treatment with apo B peptide vaccines inhibits atherosclerosis in human apo B-100 transgenic mice without inducing an increase in peptide-specific antibodies. J. Intern. Med. 264: 563-570.
16. Schiopu, A., J. Bengtsson, I. Söderberg, S. Janciauskiene, S. Lindgren, M. P. Ares, P. K. Shah, R. Carlsson, J. Nilsson, and G. N. Fredrikson. 2004. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation 110: 2047-2052. (Pubitemid 39331920)
17. -/-) mice. J. Am. Coll. Cardiol. 50: 2313-2318.
18. Fredrikson, G. N., A. Schiopu, G. Berglund, R. Alm, P. K. Shah, and J. Nilsson. 2007. Autoantibody against the amino acid sequence 661-680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events. Atherosclerosis 194: e188-e192.
19. Sjögren, P.,G. N. Fredrikson, A. Samnegard, C. G. Ericsson, J. Ohrvik, R. M. Fisher, J. Nilsson, and A. Hamsten. 2008. High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction. Eur. Heart J. 29: 2218-2226.
20. Ravetch, J. V., and S. Bolland. 2001. IgG Fc receptors. Annu. Rev. Immunol. 19: 275-290.
21. Nimmerjahn, F., and J. V. Ravetch. 2006. Fcγ receptors: old friends and new family members. Immunity 24: 19-28. (Pubitemid 43077197)
22. Nimmerjahn, F., and J. V. Ravetch. 2008. Fcγ receptors as regulators of immune responses. Nat. Rev. Immunol. 8: 34-47.
23. Bolland, S., and J. V. Ravetch. 2000. Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis. Immunity 13: 277-285.
24. McGaha, T. L., M. C. Karlsson, and J. V. Ravetch. 2008. FcγRIIB deficiency leads to autoimmunity and a defective response to apoptosis in Mrl-MpJ mice. J. Immunol. 180: 5670-5679.
25. Park, S. Y., S. Ueda, H. Ohno, Y. Hamano, M. Tanaka, T. Shiratori, T. Yamazaki, H. Arase, N. Arase, A. Karasawa, et al. 1998. Resistance of Fc receptor-deficient mice to fatal glomerulonephritis. J. Clin. Invest. 102: 1229-1238.
26. Pfeiffer, J. R., P. S. Howes, M. A. Waters, M. L. Hynes, P. P. Schnurr, E. Demidenko, F. R. Bech, and P. M. Morganelli. 2001. Levels of expression of Fcγ receptor IIA (CD32) are decreased on peripheral blood monocytes in patients with severe atherosclerosis. Atherosclerosis 155: 211-218.
27. Ratcliffe, N. R., S. M. Kennedy, and P. M. Morganelli. 2001. Immunocytochemical detection of Fcγ receptors in human atherosclerotic lesions. Immunol. Lett. 77: 169-174.
28. Hernández-Vargas, P., G. Ortiz-Muñoz, O. López-Franco, Y. Suzuki, J. Gallego-Delgado, G. Sanjuán, A. Lázaro, V. López-Parra, L. Ortega, J. Egido, and C. Gómez-Guerrero. 2006. Fcγ receptor deficiency confers protection against atherosclerosis in apolipoprotein E knockout mice. Circ. Res. 99: 1188-1196.
29. Brånén, L., L. Pettersson, M. Lindholm, and S. Zaina. 2001. A procedure for obtaining whole mount mouse aortas that allows atherosclerotic lesions to be quantified. Histochem. J. 33: 227-229. (Pubitemid 32758588)
30. Zhou, X., G. Paulsson, S. Stemme, and G. K. Hansson. 1998. Hypercholesterolemia is associated with a T helper (Th)1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J. Clin. Invest. 101: 1717-1725.
31. Nilsson, J., and G. K. Hansson. 2008. Autoimmunity in atherosclerosis: a protective response losing control? J. Intern. Med. 263: 464-478.
32. Knowles, J. W., and N. Maeda. 2000. Genetic modifiers of atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 20: 2336-2345.
33. Griffith, R. L., G. T. Virella, H. C. Stevenson, and M. F. Lopes-Virella. 1988. Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes: a possible mechanism of foam cell formation. J. Exp. Med. 168: 1041-1059.
34. Gupta, S., A. M. Pablo, X. Jiang, N. Wang, A. R. Tall, and C. Schindler. 1997. IFN-γ potentiates atherosclerosis in ApoE knock-out mice. J. Clin. Invest. 99: 2752-2761.
35. Lee, T. S., H. C. Yen, C. C. Pan, and L. Y. Chau. 1999. The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 19: 734-742.
36. Niwa, T., H. Wada, H. Ohashi, N. Iwamoto, H. Ohta, H. Kirii, H. Fujii, K. Saito, and M. Seishima. 2004. Interferon-γ produced by bone marrow-derived cells attenuates atherosclerotic lesion formation in LDLR-deficient mice. J. Atheroscler. Thromb. 11: 79-87.
37. Buono, C., C. J. Binder, G. Stavrakis, J. L. Witztum, L. H. Glimcher, and A. H. Lichtman. 2005. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc. Natl. Acad. Sci. USA 102: 1596-1601.
38. Hansson, G. K., A. K. Robertson, and C. Söderberg-Nauclér. 2006. Inflammation and atherosclerosis. Annu. Rev. Pathol. 1: 297-329.
39. Palinski, W., R. K. Tangirala, E. Miller, S. G. Young, and J. L. Witztum. 1995. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 15: 1569-1576.
40. Nilsson, J., and P. T. Kovanen. 2004. Will autoantibodies help to determine severity and progression of atherosclerosis? Curr. Opin. Lipidol. 15: 499-503.
41. Fredrikson, G. N., B. Hedblad, G. Berglund, R. Alm, J. A. Nilsson, A. Schiopu, P. K. Shah, and J. Nilsson. 2007. Association between IgM against an aldehyde-modified peptide in apolipoprotein B-100 and progression of carotid disease. Stroke 38: 1495-1500.
42. Su, K., X. Li, J. C. Edberg, J. Wu, P. Ferguson, and R. P. Kimberly. 2004. A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motifbearing FcγRIIb alters receptor expression and associates with autoimmunity. II. Differential binding of GATA4 and Yin-Yang1 transcription factors and correlated receptor expression and function. J. Immunol. 172: 7192-7199.
43. Xiang, Z., A. J. Cutler, R. J. Brownlie, K. Fairfax, K. E. Lawlor, E. Severinson, E. U. Walker, R. A. Manz, D. M. Tarlinton, and K. G. Smith. 2007. FcγRIIb controls bone marrow plasma cell persistence and apoptosis. Nat. Immunol. 8: 419-429.
44. Paul, E., A. Nelde, A. Verschoor, and M. C. Carroll. 2007. Follicular exclusion of autoreactive B cells requires FcγRIIb. Int. Immunol. 19: 365-373.
45. Boruchov, A. M., G. Heller, M. C. Veri, E. Bonvini, J. V. Ravetch, and J. W. Young. 2005. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest. 115: 2914-2923.
46. Gotsman, I., N. Grabie, R. Gupta, R. Dacosta, M. MacConmara, J. Lederer, G. Sukhova, J. L. Witztum, A. H. Sharpe, and A. H. Lichtman. 2006. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 114: 2047-2055. (Pubitemid 44706881)
47. Mallat, Z., and A. Tedgui. 2002. The role of transforming growth factor β in atherosclerosis: novel insights and future perspectives.Curr.Opin. Lipidol. 13: 523-529.
48. Pinderski Oslund, L. J., C. C. Hedrick, T. Olvera, A. Hagenbaugh, M. Territo, J. A. Berliner, and A. I. Fyfe. 1999. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. [see comments] Arterioscler. Thromb. Vasc. Biol. 19: 2847-2853.
49. + regulatory T cells in experimental atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27: 893-900.
50. Iruretagoyena, M. I., C. A. Riedel, E. D. Leiva, M. A. Gutiérrez, S. H. Jacobelli, and A.M. Kalergis. 2008. Activating and inhibitory Fcγ receptors can differentially modulate T cell-mediated autoimmunity. Eur. J. Immunol. 38: 2241-2250.
51. -/-) mice. Cytokine.